Q-omics provides the consensus-scored WIPF3 profile across patient tissues and cancer cell-line models. WIPF3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, WIPF3 is differentially expressed in 11, with the highest sampling consensus in UCEC. Additionally, WIPF3 protein abundance shows 27,416 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, and GBM as cancer lineages where WIPF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WIPF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WIPF3 survival associations across molecular data types. WIPF3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WIPF3 RNA expression–survival associations across cancer types. High WIPF3 expression shows unfavorable associations in UCEC, COAD, LGG and KIRC, but favorable associations in THCA and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for WIPF3 RNA expression.
This table summarizes WIPF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in BRCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WIPF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WIPF3 shows lower tumor expression in UCEC, BRCA and KICH and higher tumor expression in CHOL, LUAD and LUSC. The UCEC box plot shows higher WIPF3 RNA expression in normal versus tumor tissue (log2 FC = −2.410, t-test p < 0.001).
This table shows molecular features associated with WIPF3 in patient tissues and cancer cell lines. In patient samples, WIPF3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, WIPF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BONE.
